Phase I study of the oral platinum agent satraplatin (JM-216) in combination with docetaxel in treatment of advanced malignancies.
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2012
At a glance
- Drugs Docetaxel; Satraplatin
- Indications Solid tumours
- Focus Adverse reactions
- 23 Mar 2012 Actual patient number (28) added as reported by ClinicalTrials.gov.
- 23 Mar 2012 Company (Agenix) added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
- 23 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.